TSE:APS

Aptose Biosciences - APS Stock Forecast, Price & News

C$1.05

+0.04 (+3.96%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: C$0.97
▼
C$1.05
50-Day Range: C$0.60
▼
C$1.05
52-Week Range: C$0.60
▼
C$1.92

Volume: 63,138 shs
Average Volume: 19,339 shs
Market Capitalization: C$96.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$8.50

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

December 30, 2022 | finance.yahoo.com

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

December 12, 2022 | ca.finance.yahoo.com

Stocks in play: Aptose Biosciences Inc

February 5, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

September 27, 2022 | finance.yahoo.com

Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

September 13, 2022 | finance.yahoo.com

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

September 12, 2022 | benzinga.com

Aptose's New "G3" Formulation of Luxeptinib Boosts Bioavailability

July 23, 2022 | finance.yahoo.com

Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?

July 19, 2022 | finance.yahoo.com

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

February 5, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

May 9, 2022 | finance.yahoo.com

Aptose Reports Results for the First Quarter 2022

May 4, 2022 | finance.yahoo.com

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

March 8, 2022 | finance.yahoo.com

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

March 1, 2022 | finance.yahoo.com

Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference

December 16, 2021 | msn.com

Aptose Biosciences Climbs 17% to Reclaim Some Losses

December 15, 2021 | finance.yahoo.com

Insiders who purchased this year lose US$89k as Aptose Biosciences Inc. (TSE:APS) stock drops to CA$1.44

December 13, 2021 | finance.yahoo.com

HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

November 26, 2021 | finance.yahoo.com

Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options

November 24, 2021 | finance.yahoo.com

Why Investors Should Hold on to Universal Health (UHS) Stock

November 22, 2021 | finance.yahoo.com

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 11, 2021 | finance.yahoo.com

Aptose Reports Results for the Third Quarter 2021

November 4, 2021 | finance.yahoo.com

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

August 19, 2021 | finance.yahoo.com

AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints

August 18, 2021 | finance.yahoo.com

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

August 6, 2021 | finance.yahoo.com

Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

August 3, 2021 | finance.yahoo.com

Aptose Reports Results for the Second Quarter 2021

August 2, 2021 | finance.yahoo.com

We Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business Growth

July 26, 2021 | finance.yahoo.com

Were Hedge Funds Right About Cutera, Inc. (CUTR)?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Company Calendar

Today: 2/05/2023
Next Earnings (Estimated): 3/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:APS
CUSIP: N/A
CIK: N/A
Web: aptose.com
Phone: +1-647-4799828
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$8.50
High Stock Price Forecast: C$12.00
Low Stock Price Forecast: C$5.00
Forecasted Upside/Downside: +709.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 5.53
Quick Ratio: 5.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.66 per share
Price / Cash Flow: 1.60
Book Value: C$0.51 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 92,295,000
Free Float: N/A
Market Cap: C$96.91 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO

Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer

Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations

Dr. Stephen B. Howell (Age 73)
Chief Medical Officer

Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions

APS Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APS shares.
View APS analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price forecast for 2023?: 3 brokers have issued 12 month target prices for Aptose Biosciences' shares. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they anticipate the company's stock price to reach C$8.50 in the next year. This suggests a possible upside of 709.5% from the stock's current price.
View analysts price targets for APS or view top-rated stocks among Wall Street analysts.
How have APS shares performed in 2023?: Aptose Biosciences' stock was trading at C$0.78 at the beginning of the year. Since then, APS shares have increased by 34.6% and is now trading at C$1.05.
View the best growth stocks for 2023 here.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our APS earnings forecast.

What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).
What is Aptose Biosciences' stock symbol?: Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."
How do I buy shares of Aptose Biosciences?: Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Aptose Biosciences' stock price today?: One share of APS stock can currently be purchased for approximately C$1.05.
How much money does Aptose Biosciences make?: Aptose Biosciences (TSE:APS) has a market capitalization of C$96.91 million.
How can I contact Aptose Biosciences?: Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828.

This page (TSE:APS) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial